VIAMEDPHARMA - Company finances
|
EUR
|
2018
From: 2018-01-01
To: 2018-12-31
|
2019
From: 2019-01-01
To: 2019-12-31
|
2020
From: 2020-01-01
To: 2020-12-31
|
2021
From: 2021-01-01
To: 2021-12-31
|
2022
From: 2022-01-01
To: 2022-12-31
|
2023
From: 2023-01-01
To: 2023-12-31
|
2024
From: 2024-01-01
To: 2024-12-31
|
2025
From: 2025-01-01
To: 2025-12-31
|
|---|---|---|---|---|---|---|---|---|
|
Financial data
|
||||||||
| Sales revenue | 561,521 | 714,401 | 931,124 | 1,041,334 | 1,313,626 | 1,485,842 | 1,608,120 | 2,038,768 |
| Profit before tax | 101,887 | 129,285 | 158,990 | 163,591 | 254,839 | 203,367 | 220,642 | 289,453 |
| Net profit | 85,277 | 108,784 | 132,464 | 137,614 | 216,167 | 170,338 | 185,078 | 241,244 |
| Equity | 89,312 | 112,098 | 136,563 | 141,177 | 220,362 | 216,959 | 248,734 | 323,475 |
| Liabilities | 130,732 | 105,351 | 183,013 | 143,238 | 209,449 | 280,582 | 390,126 | 328,834 |
| Non-current assets | 47,396 | 31,136 | 70,541 | 78,399 | 63,490 | 105,676 | 107,946 | 101,061 |
| Current assets | 172,641 | 186,192 | 248,856 | 209,996 | 367,758 | 388,523 | 528,373 | 548,816 |
| Total assets | 220,037 | 217,328 | 319,397 | 288,395 | 431,248 | 494,199 | 636,319 | 649,877 |
|
Taxes paid
|
||||||||
| STI taxes | - | - | - | - | - | 167,206 | 181,816 | 256,849 |
| Social insurance contributions | - | - | - | - | - | 54,920 | 42,353 | 57,749 |
|
Financial indicators
|
||||||||
| Revenue change y/y | +8.2% | +27.2% | +30.3% | +11.8% | +26.1% | +13.1% | +8.2% | +26.8% |
| ROA Return on Assets (ROA). The ratio of net profit to assets. Indicates the company's efficiency. | 38.8% | 50.1% | 41.5% | 47.7% | 50.1% | 34.5% | 29.1% | 37.1% |
| ROE Return on equity. The ratio of net profit to equity. Shows the return to shareholders. | 95.5% | 97.0% | 97.0% | 97.5% | 98.1% | 78.5% | 74.4% | 74.6% |
| Profit margin Net profit margin. Shows the overall profitability of the company. | 15.2% | 15.2% | 14.2% | 13.2% | 16.5% | 11.5% | 11.5% | 11.8% |
| EBT% EBT (Earnings Before Taxes) to revenue ratio. Shows the overall profitability of the company. | 18.1% | 18.1% | 17.1% | 15.7% | 19.4% | 13.7% | 13.7% | 14.2% |
| Liabilities/Equity The debt-to-equity ratio shows the company's capital structure. | 1.5 | 0.9 | 1.3 | 1.0 | 1.0 | 1.3 | 1.6 | 1.0 |
| Revenue per employee Ratio of revenue to the average annual number of employees. Indicates company efficiency. | 106,956 | 105,837 | 106,414 | 105,899 | 137,074 | 156,404 | 183,785 | 242,229 |
Sales revenue
See Scoris data in Google Search
Mark Scoris as a favorite source. One click, no registration.
VIAMEDPHARMA - Social security debts
| From | To | Debt, € |
|---|---|---|
| 2022-12-16 | 2023-01-02 | 6.96 |
| 2022-11-21 | 2022-12-12 | 6.96 |
| 2022-11-17 | 2022-11-18 | 6.96 |
VIAMEDPHARMA - VMI tax arrears
| From | To | Overdue, € |
|---|---|---|
| 2026-04-17 | 2026-04-20 | 4134.03 |
| 2025-05-01 | 2025-05-01 | 282.41 |
VMI debt information has been collected since 2024-10-07. Debts for older periods will not be displayed.
Analysis of the company's financial position
This description was generated by artificial intelligence.
Report if inaccurate.
VIAMEDPHARMA, UAB (code 302458152) is a Private Limited Liability Company engaged in the wholesale of pharmaceutical and medical goods. In 2025, revenue reached €2.04M, rising 26.8% year on year and 37.2% over two years. Net profit increased to €241.2K, and the profit margin improved to 11.8% from 11.5% in both 2023 and 2024. The company has shown a consistent three-year growth path: revenue grew from €1.49M in 2023 to €1.61M in 2024 and €2.04M in 2025, while net profit advanced from €170.3K to €185.1K and then €241.2K. At the end of 2025, total assets stood at €649.9K, equity at €323.5K and liabilities at €328.8K. This resulted in an equity ratio of 49.8% and debt-to-equity of 1.02. Asset turnover was 3.14x. Profitability ratios remained strong, with ROE at 74.6% and ROA at 37.1%. Revenue per employee was €254.8K, and profit per employee was €30.2K.